METHODS: We described the data of a patient with CEL-NOS.
RESULTS: This case is a CEL-NOS with four mutations in CSF3R-T618I, DNMT3A Q816, ASXL1, and IDH2.
CONCLUSIONS: The patient rapidly evolves into secondary acute myeloid leukemia (AML).
方法:我们描述了CEL-NOS患者的数据。
结果:本病例为CEL-NOS,CSF3R-T618I有4个突变,DNMT3AQ816、ASXL1和IDH2。
结论:患者迅速发展为继发性急性髓性白血病(AML)。